Organization

Shoichi Maruyama

1 clinical trial

Clinical trial

The Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome （PRIME Study）

Status: Recruiting, Estimated PCD: 2026-12-31